Data as of Aug 29
| +0.005 / +0.51%|
The 1 analysts offering 12-month price forecasts for Provectus Biopharmaceuticals Inc have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50. The median estimate represents a +253.54% increase from the last price of 0.99.
There are no recommendations available.
Move your mouse over a quarter or year to see how estimates have changed over time.